Hereditary Angioedema · registered primary completion 2031-08-01 · NCT04933721
Cash of $353M against operating outflow of $136M per quarter gives roughly 2.6 quarters of runway against a registered primary completion 19.7 quarters out. On these figures the company raises capital within four quarters.
Total liabilities of $1,012M exceed total assets of $558M as of 2026-06-30 — stockholders' equity is negative.
7 approved products already carry Hereditary Angioedema on label, including ANDEMBRY, TAKHZYRO, SAJAZIR, EKTERLY. Approval would enter an occupied market.
Registered design for NCT04933721: single-arm, open-label, 139 participants (estimated). Primary outcome: Number and proportion of subjects with a treatment-related TEAE. 4 further primary outcome(s) registered.
255,535,105 shares outstanding against 274,481,105 if every outstanding option, warrant and convertible were exercised. In that case 6.9% of a gain in enterprise value would accrue to those holders rather than to current shareholders.
Designations disclosed: Breakthrough Therapy, Fast Track, Orphan Drug. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.
2 distinct molecules in 3 active company-sponsored trials; Berotralstat accounts for 2 of them at Phase 3.
Programs receiving under $250k of research spend in the quarter: Years Ended December.